You are here
Interview at EAU 2015 with Prof. Schalken, Madrid, Spain
- Detection of prostate cancer is generally done by PSA testing. Your lab developed the PCA3 test in urine. How should this test be used?
- Is PCA3 helpful in following men on active surveillance?
- Prostate cancer is clustered in families in around 5% of cases. Will genetic analysis be helpful to identify family members at risk?
- Several genetic tests, such as Prolaris and Decipher, have become available. How should these tests best be used?
- The role of the androgen receptor has returned as target in men with castration resistant prostate cancer. From a biological point of view is there a preference for either a strong antiandrogen or agents targeting the LHRH axis or should agents always be used in combination?
- Closing remarks and take home message